What does a diagnosis of atypical glandular cells with High-grade Squamous Intraepithelial Lesions (HSIL) mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding Atypical Glandular Cells with HSIL

A diagnosis of atypical glandular cells (AGC) with High-grade Squamous Intraepithelial Lesions (HSIL) represents a significant finding that requires immediate colposcopy due to the high risk of underlying cervical neoplasia, including both squamous and glandular lesions. 1, 2

What This Diagnosis Means

  • AGC represents abnormal glandular cells that cannot be classified as clearly benign or malignant, occurring in only 0.2% of cervical cytology samples 1
  • HSIL represents high-grade squamous abnormalities that encompass moderate and severe dysplasia (CIN II and III) 1
  • The combination of these findings indicates abnormalities in both the glandular and squamous cell components of the cervix 3

Clinical Significance and Risk Assessment

  • AGC can indicate significant underlying pathology in up to 38% of cases, including both squamous and glandular lesions 1
  • When HSIL is detected on Pap smear, the risk of histologic HSIL and cancer is approximately 69% 1
  • The combination of AGC with HSIL significantly increases the risk of having cervical intraepithelial neoplasia (CIN) 2 or worse compared to AGC alone 3
  • Studies show that AGC associated with HSIL has a strong correlation with squamous neoplasia on histological examination 3

Required Management

  • Immediate colposcopy with endocervical sampling is mandatory 1, 2
  • HPV DNA testing should be performed as part of the initial evaluation 1
  • Endometrial sampling is recommended for women 35 years and older or younger women with risk factors for endometrial cancer 1
  • Reflex HPV testing or repeat cytology alone is unacceptable as initial management 1

Management Algorithm

  1. Initial evaluation:

    • Colposcopy with endocervical sampling 1
    • HPV DNA testing 1
    • Endometrial sampling for women ≥35 years or with risk factors 1
  2. If colposcopy identifies CIN 2,3:

    • Proceed with appropriate treatment based on the grade of lesion 2
  3. If initial evaluation is negative or unsatisfactory:

    • A diagnostic excisional procedure (LEEP or cold knife conization) may be required 1, 2
    • This is particularly important with AGC-favor neoplasia or AIS 1
  4. Follow-up after negative initial evaluation:

    • If HPV positive: Repeat cytology and HPV testing in 6 months 1
    • If HPV negative: Repeat cytology and HPV testing in 12 months 1
    • If both tests negative on reevaluation: Return to annual cytologic testing 1

Important Considerations

  • The presence of AGC with HSIL represents a higher risk category than either finding alone 3
  • CIN is the most common pathology found in women with AGC, especially those younger than 35 years 1
  • Studies show that 35% of patients with AGC may have underlying HSIL on histological examination 4
  • The combination of AGC with HSIL is strongly associated with squamous neoplasia but not necessarily with adenocarcinoma 3

Pitfalls to Avoid

  • Do not rely solely on HPV testing or repeat cytology for initial management 1
  • Do not underestimate the significance of this finding - even with negative HPV testing, the risk of significant disease remains high 2
  • Avoid delaying colposcopy and endocervical sampling, as this combination of findings indicates high risk for underlying significant pathology 1, 2
  • Remember that colposcopy alone can miss a significant number of lesions, particularly glandular lesions, which may require excisional procedures for definitive diagnosis 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of High-Grade Squamous Intraepithelial Lesions (HSIL)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.